Results 1 to 10 of about 127,263 (196)

Glucagon-like peptide 1 (GLP-1) [PDF]

open access: yesMolecular Metabolism, 2019
Background: The glucagon-like peptide-1 (GLP-1) is a multifaceted hormone with broad pharmacological potential. Among the numerous metabolic effects of GLP-1 are the glucose-dependent stimulation of insulin secretion, decrease of gastric emptying ...
T.D. Müller   +24 more
doaj   +13 more sources

Glucagon-Like Peptide-1

open access: yesJACC: Basic to Translational Science, 2016
Glucagon-like peptide-1-(7-36) amide (GLP-1) is a human incretin hormone responsible for the release of insulin in response to food. Pre-clinical and human physiological studies have demonstrated cardioprotection from ischemia-reperfusion injury.
Joel P. Giblett, BM, BSc   +3 more
doaj   +3 more sources

Potential role of glucagon like peptide 1 in taste receptors [PDF]

open access: yesFrontiers in Endocrinology
The perception of taste is a complex physiological process that extends far beyond the simple detection of flavor molecules, serving as a critical interface between nutrient sensing, metabolic regulation, and feeding behavior.
Jose Luis Eduardo Doval-Caballero   +11 more
doaj   +2 more sources

Glucagon-like peptide-1 and glucagon-like peptide-2 regulation during human liver regeneration

open access: yesScientific Reports, 2023
Accumulating evidence suggests that metabolic demands of the regenerating liver are met via lipid metabolism and critical regulators of this process. As such, glucagon-like peptide-1 (GLP-1) and glucagon-like peptide-2 (GLP-2) critically affect hepatic ...
Markus Ammann   +9 more
doaj   +3 more sources

Glucagon-like peptide-1 receptor agonists in orthopaedics [PDF]

open access: yesSICOT-J
Glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1RA) help people control blood glucose and lose weight. They may also help with bone metabolism, healing fractures, keeping joints healthy, and recovering after surgery.
Mavrogenis Andreas F.   +7 more
doaj   +2 more sources

Equine glucagon-like peptide-1 receptor physiology [PDF]

open access: yesPeerJ, 2018
Background Equine metabolic syndrome (EMS) is associated with insulin dysregulation, which often manifests as post-prandial hyperinsulinemia. Circulating concentrations of the incretin hormone, glucagon-like peptide-1 (GLP-1) correlate with an increased ...
Murad H. Kheder   +4 more
doaj   +5 more sources

Association Between Glucagon‐Like Peptide‐1 Receptor Agonists and Risk of Arrhythmias [PDF]

open access: yesJournal of Arrhythmia
Background Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), initially designed to treat diabetes mellitus (DM), have demonstrated the potential to mitigate obesity‐related cardiovascular risks.
Vikash Jaiswal   +12 more
doaj   +2 more sources

Adult human biliary tree stem cells differentiate to β-pancreatic islet cells by treatment with a recombinant human Pdx1 peptide [PDF]

open access: yes, 2015
Generation of β-pancreatic cells represents a major goal in research. The aim of this study was to explore a protein-based strategy to induce differentiation of human biliary tree stem cells (hBTSCs) towards β-pancreatic cells.
Alvaro, Domenico   +15 more
core   +15 more sources

Glucagon-like peptide-1, glucagon-like peptide-2, and lipid metabolism [PDF]

open access: yesCurrent Opinion in Lipidology, 2016
Glucagon-like peptide-1 (GLP-1) is the best known incretin hormone able to potentiate glucose-induced insulin secretion. Moreover, GLP-1 is currently under intensive investigation as a potential crucial mediator of beneficial metabolic effects after bariatric surgery, because of its eating inhibitory, antiobesity, and antidiabetes effects.
Thomas A. Lutz, Elena Osto
openaire   +2 more sources

Association of glucagon‐like peptide‐1 receptor‐targeted imaging probe with in vivo glucagon‐like peptide‐1 receptor agonist glucose‐lowering effects

open access: yesJournal of Diabetes Investigation, 2020
Aims/Introduction Glucagon‐like peptide‐1 receptor agonists (GLP‐1RA) are used for treatment of type 2 diabetes mellitus worldwide. However, some patients do not respond well to the therapy, and caution must be taken for certain patients, including those
Takaaki Murakami   +5 more
doaj   +1 more source

Home - About - Disclaimer - Privacy